Further Removal of Factor V Related Antigen From Bovine Thrombin by Utilizing a Membrane-Filtration Step

Abstract

Topical bovine thrombin is commonly used during surgery to maintain hemostasis and is rarely associated with abnormalities in hemostasis, including coagulopathies and bleeding. Coagulopathies may be related to the formation of cross-reactive antibodies to bovine factor V. Effectiveness of a new filtration step to remove factor V/Va from bovine thrombin was evaluated. A highly sensitive and specific Western blot capable of detecting minute amounts of factor V/Va and/or its fragments was developed. Samples were evaluated for bovine factor V related antigens using the Western blot method and a competitive enzyme-linked immunosorbent assay. Factor Va light chain fragment levels were detectable in crude thrombin and chromatographically purified thrombin but not in chromatographically purified and virally filtered preparations. Therefore, inclusion of the viral-filtration step during purification of thrombin is effective in reducing factor V or its fragments to undetectable levels, thus enhancing product purity.

Keywords

factor Va bovine thrombin Western blot virus filtration topical hemostat

References

Block J. Severe blood loss during spinal reconstructive procedures: the potential usefulness of topical hemostatic agents. Med Hypotheses. 2005;65:617-621.

Renkens KL Jr , Payner T. , Leipzig T. , et al. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine. 2001;26:1645-1650.

Sabel M. , Stummer W. The use of local agents: surgicel and Surgifoam. Eur Spine J. 2004;13:S97-S101.

Gabay M. Absorbable hemostatic agents. Am J Health Syst Pharm. 2006;63:1244-1253.

Oz M. , Rondinone JF , Shargill NS FloSeal Matrix: new generation topical hemostatic sealant. J Card Surg. 2003;18:486-493.

Bishop P. , Lewis K. , Schultz J. , et al. Comparison of recombinant human thrombin and plasma-derived human α-thrombin. Semin Thromb Hemost. 2006;32:86-97.

Lundblad RL , Bradshaw RA , Gabriel D. , et al. A review of the therapeutic uses of thrombin. Thromb Haemost. 2004;91:851-860.

Davie E. , Kulman J. An overview of the structure and function of thrombin. Semin Thromb Hemost. 2006; 32:3-15.

Yonemura H. , Imamura T. , Soejima K. , et al. Preparation of recombinant alpha-thrombin: high-level expression of recombinant human prethrombin-2 and its activation by recombinant ecarin . J Biochem (Tokyo). 2004;135: 577-582.

10.

Zehnder JL , Leung LL Immunological consequences of topical bovine thrombin. Am J Pathol. 2001;159:2371.

11.

Schoenecker JG , Hauck RK , Mercer MC , et al. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose α1-3 galactose. J Clin Immunol. 2000;20:434-444.

12.

Leung LL Perioperative evaluation of bleeding diathesis. Hematology Am Soc Hematol Educ Program. 2006:457-461.

13.

Nelson PA , Powers JN , Estridge TD , et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res. 2001;58:710-719.

14.

Lawson JH , Lynn KA , Vanmatre RM , et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg. 2005;79:1037-1038.

15.

Sarfati MR , Dilorenzo DJ , Kraiss LW , et al. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg. 2004;18:349-51.

16.

Suzuki K. , Dahlback B. , Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem. 1982;257:6556-6564.

17.

Bollag DM , Rozycki MD , Edelstein SJ Immunoblotting. In: Henderson D , ed. Protein Methods. 2nd ed. Wilmington, DL: Wiley-Liss Inc.; 1996:195-227.

18.

Tomizawa Y. Clinical benefits and risk analysis of topical hemostats: a review. J Artif Organs. 2005;8:137-142.

19.

Cmolik BL , Spero JA , Magovern GJ , et al. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg. 1993;105:222-228.

20.

Ortel TL , Charles LA , Keller FG , et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol. 1994; 45:128-135.

21.

Ortel TL , Mercer MC , Thames EH , et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001;233:88-96.

22.

Winterbottom N. , Kuo JM , Nguyen K. , et al. Antigenic response to bovine thrombin exposure during surgery: a prospective study of 309 patients. J Appl Res Clin Exp Ther. 2002;2:1-12.